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Sufficient data exist to implicate the monocyte-mac-
rophage as the major source of prostaglandins in mon-
ocyte-macrophage-T lymphocyte interactions. Prosta-
glandin (PG) E 2, a major prostaglandin synthesized by 
human monocyte-macrophages is able to modulate a 
variety ofT lymphocyte reactivities including blastoge-
nesis, lymphokine secretion, and cytotoxicity. The effect 
of PGE2 on T lymphocyte function varies according to 
the primary activating stimulus, the specific response 
under investigation, as well as the population ofT lym-
phocytes involved. Some immunologic abnormalities 
found in clinical disease may in part derive from altera-
tions occurring in the synthesis of PGE2 by monocyte-
macrophages or in the response of T lymphocytes to 
PGE2. 
Cells belonging to the monocyte-macrophage line (subse-
quently designated as M<I>s) perform a variety of immunological 
functions required for the normal reactivity ofT lymphocytes. 
These include the appropriate presentation of antigenic deter-
minants as well as the synthesis and release of various soluble 
factors which serve to enhance or suppress T lymphocyte 
reactivity (reviewed in reference 1). Included among these 
soluble factors are certain members of the prostaglandin (PG) 
family which consists of a group of oxygenated cyclopentane 
derivatives synthesized from polyunsatmated fatty acids (re-
viewed in references 2 and 3). This paper will discuss the 
concept ofM<I>-dependent modulation ofT lymphocyte reactiv-
ity through the synthesis of PGE2. 
NATURE OF THE PGE2-PRODUCING CELL 
The frequently repeated statement that PGs are ubiquitous 
products of cellular metabolism has lead to the assumption that 
all cells synthesize these products. However, existing studies 
suggest that, in the context of M<I>-T lymphocyte interactions, 
the synthesis of PGE2 is a property of the M<I> but not of the T 
lymphocyte. For example, deletion ofM<I>s from human periph-
eral blood mononuclear cells or from animal spleen cells leads 
to a loss in the recovery ofPGE2 from the non-M<I> mononuclear 
cells whereas the isolated M<I>s readily synthesize PGE2 (4-10). 
Moreover, removal ofT lymphocytes from murine spleen cell 
preparations fails to alter the levels of P_GE2 generate~ by the 
whole spleen cell preparation [6]. The Figure shows thm-layer 
radiochromatographic data from our laboratory demonstratmg 
that human peripheral blood M<I>s (>95% esterase positive) but 
not T lymphocytes (>90% T cells) are able to convert the 
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Abbreviations: 
MIF: macrophage inhibitory factor 
PG: prostaglandin 
PHA: phytohemagglutinin 
PWM: pokeweed mitogen 
radiolabeled PG precmsor '''C-arachidonic acid into '''C-PGE2. 
We have recently found that PGE2 synthesis among human 
peripheral blood M<I>s reflects a heterogeneous contribution 
from different M<I> subpopulations, some of which release sub-
stantially more than do others [11]. While the significance of 
the heterogeneity is cmrently unclear, the data imply that 
functionally, not all M<I>s have equivalent potential for provid-
ing PGE2 as a regulatory product. Previous studies have dem-
onstrated that populations of human M<I>s also differ with 
regard to other immunoregulatory capabilities [12]. 
Studies from several laboratories, including our own, have 
shown that in addition to PGE2, human M<I>s also synthesize 
PGE, and PGF2 .. as well as the PG-related thromboxane B2 
(although the presence of thromboxane as a platelet-derived 
contaminant has not been completely excluded) [7,10,11]. There 
is conflicting data with regard to the synthesis of other PGs (ie. 
PGD2, PGiz (prostacyclin) etc.) by M<I>s probably due to vari-
ations in sensitivity of the assays employed or to the purity and 
somce of the M<I>s assayed [10,13]. However, PGE2 has so far 
been the major PG associated with having an immunoregula-
tory potential (reviewed in reference 3). PGE, has, in general, 
been found to be equally as potent as PGE2, but the levels 
generated by human peripheral blood M<I>s are more than 10-
fold lower than those of PGE2 [11]. This value is consistant 
with the finding that arachidonic acid, the precmsor of the 2-
series PGs (ie., PGE2, PGF2" etc.) constitutes approximately 
20% of the fatty acids esterified to human M<I> membrane 
phospholipids whereas dihomo-y-linolenic acid, the precmsor 
of the 1-series PGs (ie. PGE, PGF,"' etc) appears to constitute 
less than 1% of the esterified fatty acids [15]. PGF2,. , at least in 
the experimental models studied, has not exhibited immune-
regulatory activity. 
The Table lists the various agents capable of stimulating 
PGE2 synthesis by human peripheral blood M<I>s. Studies in-
volving animal M<I>s have shown, in addition, that purified 
protein derivative and partially pmified macrophage inhibitory 
factor (MIF), a lymphokine, are also stimulatory [16]. Despite 
the variety of factors capable of stimulating in vitro PG syn-
thesis by M<I>s, some specificity in the nature of the stimuli does 
appear to exist since a lymphocyte mitogen such as concana-
valin A (Con A) directly induces PGE2 synthesis by human 
peripheral blood'M<I>s whereas the mitogens phytohemaggluti-
nin (PHA) and pokeweed mitogen (PWM) apparently do not 
[9]. However, PHA and PWM have been reported to stimulate 
PGE2 synthesis by whole peripheral blood mononuclear cells 
[ 4,18] . These observations could be explained by the fact that 
PHA is capable of releasing free arachidonic acid from periph-
eral blood lymphocytes [19] which although incapable of syn-
thesizing PGs themselves, would provide the necessary sub-
strate for PGE2 synthesis by the resident M<I>s. Th.is possibility 
is strongly supported by the observation that '"C-arach.idonic 
acid is converted to PGE2 by isolated peripheral blood M<I>s but 
not by peripheral blood T lymphocytes or by the other remain-
ing peripheral blood mononuclear cells (see the Figme). Thus 
the T lymphocyte could potentially regulate its own functions 
by stimulating PGE2 synthesis in M<I>s either through the 
release of lymphokines such as MIF [16] or by supplying the 
free substrate to the M<I>s for PGEz synthesis. 
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Factors affecting PGEz synthesis by human peripheral 
blood M<l>s 
Stimulation 
Aggregated myeloma lgG [9] 
Antigen-antibody complexes [17] 
Concanavalin A [9] 
Cytochalasin B [9] 
Endotoxin [8,9] 




Fab fragments [9] 
Latex particles [9] 
Phytohemagglutinin [9] 
Pokeweed mitogen [9] 











PGEz synthesis by human T cells and M<l>s. Human peripheral blood 
T cells and M<l>s were isolated as previously described [12,28]. Cells 
were incubated in tris buffer pH 7.4 containing 0.05mM EDTA for 30 
min at 37°C following the addition of 1.3 flg (500,000 dpm) of [l-14C] 
arachdonic acid (AA). Ether extracts of acidified cu lture media (pH 3) 
were subjected to th in-layer chromatography on silica gel G using the 
organic phase of the solvent system: ethyl acetate:2,2,4-trimethylpen-
tane:acetic acid:water (44:20:8:40). Radioactive peaks were detected 
using a B~rthold LB2760 TLC sc_anner. A: Standards of [5, 6, 8, 11, 12, 
14, 15(n)-· H] PGEz, sp.act. 160C!/mmol; [1-14C] AA, sp. act. 56.5mCi/ 
mmol. B. 20 X 10" T cells. C. 20 X 10'; Mcps. 0 = origin; SF = solvent 
front; vertical axis= relative radioactivity. 
MODULATION OFT LYMPHOCYTE REACTIVITY BY 
PGEz 
The in vitro effects of PGEz on such T lymphocyte responses 
as mitogen-induced blastogenesis [5,18-22], lymphokine secre-
tion [16,23-25] and cytotoxicity [26,27] have been well docu-
mented. While the most frequently observed effect of PGEz on 
these responses has been inhibitory, the effect on the release of 
a lymphokine such as osteoclast activating factor has been 
stimulatory [24]. Furthermore, recent studies from our labora-
tory have shown that, even in regard to a single T lymphocyte 
response such as mitogen-induced blastogenesis, the modula-
tory effect of PGE2 depends on the T lymphocyte subpopulation 
in question [28]. We observed that subpopulations of human 
peripheral blood T lymphocytes derived from peripheral blood 
Vol. 74, No. 5 
mononuclear cells by density gradient fractionation show dia-
metrically opposite responses to PGEz following mitogenic stim-
ulation with PHA; that is, the blastogenic response of T lym-
phocytes segregating to a low-density region of the gradient is 
enhanced by PGE2 whereas the response of cells segregating to 
a higher density region of the gradient is suppressed. The 
degree of blastogenic suppression caused by PGE2 in the un-
fractionated T lymphocytes was roughly the algebraic sum of 
the individual reactivities of the subpopulations. 
While the studies cited above involve the addition of exoge-
nous PGE2 to the responding cells, several observations suggest 
that endogenous production of PGEz by M<t>s is involved in the 
normal regulation of the primary responses studied. First, re-
moving the M<I>s from the experimental system or adding 
inhibitors of PG synthesis without removing the M<t>s alter the 
normally observed (control) T lymphocyte response in the · 
direction expected by the removal of PGE~ [5,22]. Second, the 
levels of PGE2 recovered from the various in vitro systems 
studied (10- 8-10- 7 M) fall within the range which when added 
exogenously modulate T lymphocyte reactivity [10,11,16,18, 
28]. 
It is important to remember that the effects of PGE2 on T 
lymphocyte reactivity are modulatory in nature, altering a 
response already initiated by some other primary stimulus. 
Furthermore, the effect of PGEz on T lymphocyte reactivity 
can vary and must, therefore, be defined in the context of the 
primary stimulus [21,22], the specific reactivity under study 
[23,24] and the population or subpopulation ofT lymphocyte 
in question [28]. 
CLINICAL CORRELATIONS 
Based on the data reviewed above, it could be postulated 
that changes in PGE2 production by M<t>s or in T lymphocyte 
response to M<t>-derived PGEz could result in altered immuno-
logic reactivity of T lymphocytes in clinical disease. In fact, 
evidence has been presented that the hyporesponsiveness ofT 
lymphocytes to PHA in anergic patients with Hodgkin's disease 
results in part from the excessive synthesis of PGEz by the 
peripheral blood M<t>s [29]. Blocking PG synthesis with indo-
methacin or removing the PGEz - producing M<t>s from the 
PBMC restored the blastogenic response virtually to control 
values. A fourfold increase in PGE2 by the whole peripheral 
blood mononuclear cells was documented. Other investigators 
have described a similar phenomenon but have shown that the 
increased levels of PGE2 produced by mononuclear cells from 
patients Hodgkin's disease result from an increase in the abso-
lute number of peripheral blood M<t>s [30]. Additional data 
·suggest that the peripheral blood lymphocytes in Hodgkin's 
disease may also induce greater synthesis of PGEz from M<I>s 
[30]. This could conceivably result from an increased release of 
free arachidonic acid or PG-stimulating lymphokine (ie., MIF-
reference 16) by the lymphocytes of these patients. While other 
studies demonstrate that non-PG related suppression of T 
lymphocyte blastogenesis may occm in Hodgkin's disease 
[31 ,32], increased PGE2 synthesis by M<t>s may indeed represent 
one factor contributing to altered T lymphocyte reactivity in 
these patients. A similar situation has been described in patients 
with active sarcoidosis demonstrating depressed cell-mediated 
immunity [33]. 
Whether or not the restoration of the in vitro blastogenic 
response ofT lymphocytes by the use of PG synthesis inhibitors 
leads to a reversal of clinical anergy has not yet been docu-
mented in the patients with Hodgkin's disease or active sar-
coidosis. However, a report has been made documenting such 
a reversal of both clinical anergy and suppressed in vitro 
blastogenesis in a patient with adult acquired hypogammaglob-
ulinemia [34]. Interestingly, reversal was noticed only during 
the period of indomethacin therapy. 
Studies on other diseases involving altered immunologic sta-
tus also show changes in the response of T lymphocytes to 
May 1980 PROSTAGLANDIN E2 AND MACROPHAGE-T LYMPHOCYTE INTERACTIONS 299 
PGE2. For example, in multiple sclerosis, while T lymphocyte 
blastogenesis is sensitive to suppression by PGE2 [35], the 
release of the lymphokine LIF (leukocyte migration inhibitory 
factor), unlike in cells from normal individuals, apperu·s resist-
ant to PGE2-mediated suppression [36]. It has been hypothe-
sized that a similar refractoriness of T lymphocytes to the 
modulatory effects of PGE2 could explain certain altered im-
munologic responsiveness observed in patients with rheumatoid 
arthritis [37]. 
Clearly, further investigation is required to define the roles 
ofPGE2 and possibly other M<I>-derived PGs or related products 
(thromboxanes, hydroxy fatty acids, and possibly leukotrienes 
[38]) in both physiologic and pathophysiologic aspects of M<I>-
T lymphocyte interactions. Nevertheless, the data presented 
and reviewed in this paper strongly implicate PGEz as an 
important agent through the release of which M<I>s may mod-
ulate T lymphocyte reactivity. 
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DISCUSSION 
DAVIES: How do you chru·acterize your periphera l blood mononu-
clear phagocyte subpopulations? 
GoLDYNE: In our studies, the subpopulations of monocytes are only 
defined by where they sediment in a discont inuous BSA density gra-
dient. The ident ification of these subpopu lations as monocytes is made 
on the basis of esterase positivity, adherence, a nd phagocytosis. 
DAVIES: What is the minimum period of t ime needed for responding 
lymphocytes to be exposed to exogenous PGE2 in order to demonstrate 
an effect on "H-Tell· incorporation? 
GOLDYNE: I do not believe that that parameter has been examined. 
Webb and Nowowiejski (Cell lmmun.ol 41:72-85, 1978) however, 
showed that PGE2 suppression of lymphocyte blastogenesis occurred 
only if the PGE" was added between 0 a nd 24 hr after mitogen 
stimulation. More recent ly, Muscoplat a nd colleagues (ln.(ecl Inun.un.ol 
26:311-315, 1979) showed that maximum suppression of lymphocyte 
blastogenesis by PGEt occurred only if the prostagla ndin was added 
within 4 hr following exposUJ·e to PHA but that by 24 hr a fter PHA 
exposure PGEt could no longer affect the blastogenic reactivity. How-
ever, this response pattern could be uniqu e to PHA and ConA since 
these authors demonstrated that using PPD as the mitogen, PGE2 was 
still able to suppress mitogenesis significantly even when added at 24 
hr after PPD exposure. Furthermore, in ligh t of our studies, it would 
appear that the loss of PGEt-induced blastogenic suppression in re-
sponse to PHA in fact represents the masking of a continuous suppress-
ability of one subpopulation of T cells by a n increased blastogenic 
response induced by PGEt in a nother subpopulation ofT cells. 
DAVIES: But have a ny experiments been done where the lympho-
cytes have been pulsed with exogenous prostaglandin and then the 
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prostaglandin taken away and then the cells examined to see whether 
there is a long lasting effect of that pulse. 
GOLDYNE: I am no t aware of a study that has carried out that 
particular experiment with blastogenic reactivity. 
LICHTENSTEIN: Severa l years ago, Henry Bourne, Chris Henney and 
I showed that the addition of PGE2 elevated cAMP quite rapidly and 
the level a lso feU rapidly when PGE2 was washed away. PGE2 inhibits 
T cell cytotoxicity and this inhibitory effect follows the cAMP level, ie., 
if you wash PGE away, the inhibition is also lost. 
GoLDYNE: What I see as important in the context of an evolving 
understanding of prostaglandin function is that the old dogma that 
PGE2, for example, has only one effect on a given cell system (ie. T 
lymphocytes) has evolved because the heterogeneity of such cell sys-
tems in terms of response to prostaglandins has only recently begun to 
be considered and appropriately examined. Our awareness of such 
heterogeneity in response to a given prostaglandin may lead to a better 
understanding of the roles of prostaglandins in cellular interactions. 
GREEN: Ordinary immunologists should be more concerned with 
prostaglandin production by macrophages. The production of prosta-
glandins may influence many types of immunological reactions, in vitro, 
in which macrophages are present and confuse the interpretation of 
the results of proliferative as well as cytotoxic assays. 
CO HN: What is the half life of PGE2 in these cultur es? Is most of it 
bound to albumin? 
GOLDYNE: When we added tritiated PGE2 to the monocyte cul tures, 
no noticeable breakdown could be appreciated by thin-layer chroma-
tography at 24 hr after addition so that the half life in this in vitro 
system appears to be fairly long. In regard to PGE2 binding to albumin, 
Gueriguian (J Pharmacal Exp Therap 197:391-401 , 1976), Raz 
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(Biochim Biophys Acta 280:602-613, 1972) and Unger (J Pharm Plwr· 
macol24:470-477, 1972) have demonstrated a weak, noncovalent bind-
ing between PGE2 and serum albumin. From Unger's data on equilib-
rium dialysis of"H-Tdr PGE, against various concentrations of albumin, 
very li ttle, ie. less than 5%, would be bound to albumin in our cul tures 
where we have only 5-10% fetal calf serum. 
CLARK: Upon routine isolation of mononuclear ce lls, I have been 
intrigued by the observation that platelets often rosette around mono-
nuclear cells (?monocytes). Would you comment further on your find-
ings of thromboxane production by macrophages? 
GoLDYNE: All that I can say is that we too have noticed this 
phenomenon of platelet adherence to the monocytes, and t he throm-
boxane synthesis by these monocytes could possibly accoun t for this 
observation. 
AusTIN: What are the functional and/or biological correlations of 
high and low density T cells? Do the PGE2 responsive cells have lower 
levels of baseline cAMP? 
GoLDYNE: We are just beginning to exa mine the possible functional 
correlations of the high and low density T cell popu lations. The low 
density T cells whose blastogenic reactivity was enhanced by PGE2 had 
a baseline level of cAMP roughly twice that of the high density cells 
whose blastogenic reactivity was suppressed by PGE2• 
LICHTENSTEIN: ln fact you showed that high density lymphocytes 
were inhibi ted by PGE2 and low density lymphocytes were enhanced. 
Both cell preparat ions showed about 2.5 fold increase in cAMP after 
PGE2. The critical point, I think, was that the low density cells started 
with approximately twice the cAMP level of the high density ce lls so 
that while the percentage increase was similru·, the absolu te levels were 
quite different. 
